Answers are grounded in this paper and cite their sources.
Biocatalysis shows promise for greener asymmetric butenolide synthesis in Streptomyces avermitilis, suggesting sustainable alternatives.
Butenolides are important features of many bioactive compounds. Current petrochemical-based methods for asymmetric butenolide synthesis are unsustainable. Biocatalysis could enable cheaper, greener, and more sustainable alternatives. However, known butenolide biosynthetic pathways are complex and challenging to harness. Here we show that avenolide, a 4-alkylbutenolide that regulates avermectin production in Streptomyces avermitilis, is assembled from a fatty acyl thioester by a multifunctional flavoenzyme and an iterative cytochrome P450. The flavoenzyme catalyzes homochiral 4-alkylbutenolide formation via successive desaturation, hydroxylation, and lactonization reactions, using dioxygen as the sole stoichiometric reagent. This lays the foundation for development of sustainable biocatalytic asymmetric butenolide synthesis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: